Warsh's hawkish Fed debut sinks stocks even as a US-Iran deal cools oil
New Fed Chair Kevin Warsh used his first press conference to stress price stability, drop forward guidance, and let fresh projections show numerous policymakers now pencil in a rate hike this year. Stocks sold off across the board — Dow -1%, S&P 500 -1.2%, Nasdaq -1.3% — while the dollar pushed to a two-month high and the yen slid toward intervention territory. The selloff came despite a genuine geopolitical positive: the US and Iran electronically signed a 14-point memorandum extending their ceasefire, which dragged oil lower and lifted overnight futures. Beneath the index red, the leadership tells a different story: AI-power and chip-equipment names kept humming (ASML, Applied Materials and Lam at record highs; Cummins, GE Vernova, Arcosa, Jabil bid), biotech ripped on a regulatory thaw (UniQure +~80% on an FDA gene-therapy refile), and Robinhood jumped after cutting 10% of staff into record June volumes. The tension to watch: a market that is still paying ~27x for the S&P against a 4.5% risk-free 10-year, now facing a Fed willing to hike rather than cut.
Warsh's hawkish Fed pivot
Warsh's first FOMC held rates steady but scrapped forward guidance and delivered projections in which numerous officials see a hike this year; he said he was unconcerned by the market's negative reaction. Rate-hike odds, not cuts, are now the base case being priced — a regime change from the prior chair. Growth stocks outperformed on the day but the broad tape fell and rates spiked.
US-Iran deal pressures oil
The US and Iran signed a 14-point memorandum of understanding extending their ceasefire and framing a path to peace, reportedly inked in Versailles. Oil fell and Asian equities steadied; overnight US futures climbed on the news even with the hawkish Fed overhang. Durability is the open question — this is a framework, not a final settlement.
AI-power and chip-gear leadership persists
Despite the rate scare, the AI build-out trade led: ASML, Applied Materials and Lam hit record highs; Bernstein lifted AMD, Arm and Intel on a 'CPU renaissance'; Cummins flirted with a breakout on an AI data-center power deal; GE Vernova jumped ~7% on an analyst initiation, and supplier Arcosa neared a breakout; Jabil beat-and-raised on AI infrastructure demand before fading.
Biotech regulatory thaw
UniQure rocketed ~80% after the FDA cleared it to refile its Huntington's disease gene therapy, and IBD framed broader 'regulatory leniency' lifting Atara, Biohaven and Moderna. TG Therapeutics is up ~70% year-to-date as it challenges Roche. The read-through: a friendlier FDA posture is rewarding clinical-stage names.
SpaceX's first down day post-IPO
After the largest IPO ever, SpaceX logged its first full-day price decline (~-5%), prompting 'is it a buy' chatter and reminders that the stock is headed for index-fund inclusion. Coupled with 'inflation heating up' headlines, it is feeding a froth/crash debate worth treating skeptically.
Dollar strength and yen intervention risk
The dollar clung to a two-month high on rate-hike bets while the yen slid, prompting Japan to vow it could act 'any time' on the currency. A hawkish Fed surprise also pressured the Indian rupee. FX volatility is becoming a second-order channel of the Fed repricing.